Hospira Will Not Be Reheard On Retacrit Biosimilar
Firm Had Petitioned Over Infringement And Damages Affirmation
Hospira has been frustrated again in long-running litigation concerning its Retacrit biosimilar to Amgen’s Epogen, in a case closely watched by the biopharma industry as it addressed what constitutes a safe harbor for a biosimilar applicant.
You may also be interested in...
Federal Circuit affirms jury's $70m award to Amgen and finding that some Hospira biosimilar batches were not protected by the safe harbor. Decision conveys how biosimilar makers can obtain this protection from infringement suits.
India’s Cipla has received the first US approval for a generic rival to Nexium delayed-release oral suspension in the US. The firm recently declared its intention to direct funds to more complex formulations in the US but nevertheless continues to grow its vast portfolio in the market.
California-based Nivagen is continuing to raise money to push through a number of generic launches in the US this year, the company’s founder and chief Jay Shukla told Generics Bulletin.